1. Chronic HCV Infection and CKD

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Treatment of Patients With Chronic HCV Infection and CKD

4. HCV and CKD: A Tale of 2 Patient Populations

5. Patients With CKD Who Acquire HCV infection

6. Patients With CKD Who Acquire HCV infection (cont)

7. Patients With Chronic HCV Infection Who Develop CKD

8. Renal Diseases Associated With Chronic HCV Infection

9. Renal Diseases Associated With Chronic HCV Infection (cont)

10. Patients With CKD and Chronic HCV Infection: Implications for Practice

11. Burden of Disease

12. Treatment of Patients With CKD and Chronic HCV Infection: First-Generation DAAs Provided Promise of Better Outcomes

13. Dose Adjustments of All-Oral HCV Therapies in Patients With CKD

14. RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin

15. C-SURFER: Elbasvir/Grazoprevir

16. Veterans Affairs System Study: Elbasvir/Grazoprevir

17. EXPEDITION-4: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD

18. CERTAIN-1 and CERTAIN-2: Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD

19. CERTAIN-1 and CERTAIN-2: Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and CKD (cont)

20. Sofosbuvir Not Recommended for Patients With GFR <30 mL/min/1.73 m2

21. Ledipasvir/Sofosbuvir in Patients With Chronic HCV Infection and CKD

22. Treating Chronic HCV Infection in Patients With Mild to Moderate Renal Impairment With DAA Agents

23. Treating Chronic HCV Infection in Patients With eGFR <30 mL/min/1
Treating Chronic HCV Infection in Patients With eGFR <30 mL/min/1.73 m2

24. Summary

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)